Clinical Profile of Methotrexate-Resistant Juvenile Localized Scleroderma

    January 2019 in “ Acta dermato-venereologica ”
    Jean François Hardy, F. Boralévi, S. Mallet, Natalia Cabrera, Alexandre Belot, Alexandria T. Phan, S Barbarot, A. Duriez-Lasek, C. Chiavérini, T. Hubiche, Etienne Mahé, É. Bégon, E. Bourrat, O. Boccara, H. Aubert, M. Grall Lerosey, C. Droitcourt, Maryam Piram, J. Mazereeuw‐Hautier
    Image of study
    TLDR Some children with localized scleroderma are rarely resistant to methotrexate, and no common profile for resistance was found.
    The study, which included 57 children with active localized scleroderma treated with methotrexate (MTX) for at least 4 months, found that only 4 patients (7%) were resistant to MTX treatment, and no common clinical profile could be identified among these resistant patients. Despite exploring potential reasons for MTX resistance, such as insufficient dosage and individual pharmacokinetic variations, the study concluded that children with localized scleroderma are rarely resistant to MTX. It also suggested that higher dosages of MTX and the inclusion of corticosteroids might be worth investigating in future research to better understand and manage MTX resistance in juvenile localized scleroderma.
    Discuss this study in the Community →